We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $143M
1-Year Est. Return 102.52%
This Fund
S&P 500
This Quarter Est. Return
+21.15%
1 Year Est. Return
+102.52%
3 Year Est. Return
+167.58%
5 Year Est. Return
+215.85%
10 Year Est. Return
+1,289.38%
AUM
$143M
AUM Growth
+$22.6M
Cap. Flow
+$11.4M
Cap. Flow %
7.98%
Top 10 Hldgs %
39.65%
Holding
91
New
14
Increased
17
Reduced
18
Closed
9

Top Buys

Rank Stock Value
1
IRTC icon
iRhythm Holdings
IRTC
+$3.03M
2
ORKA
Oruka Therapeutics
ORKA
+$2.8M
3
SMMT icon
Summit Therapeutics
SMMT
+$2.67M
4
CBIO
Crescent Biopharma
CBIO
+$2.37M
5
DFTX
Definium Therapeutics
DFTX
+$1.94M

Top Sells

Rank Stock Value
1
EVMN
Evommune Inc
EVMN
+$13.5M
2
GILD icon
Gilead Sciences
GILD
+$905K
3
RAPP
Rapport Therapeutics
RAPP
+$835K
4
BOLD
Boundless Bio
BOLD
+$746K
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$698K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
51
Alnylam Pharmaceuticals
ALNY
$35.4B
$695K 0.49%
2,310
– –
ASND icon
52
Ascendis Pharma A/S
ASND
$17.8B
$685K 0.48%
2,570
-230
-8% -$53.7K
PFE icon
53
Pfizer
PFE
$164B
$662K 0.46%
27,500
– –
ARDX icon
54
Ardelyx
ARDX
$958M
$624K 0.44%
122,394
– –
PRVA icon
55
Privia Health
PRVA
$2.64B
$621K 0.43%
24,136
-3,000
-11% -$69.5K
PTCT icon
56
PTC Therapeutics
PTCT
$5.96B
$609K 0.43%
7,470
+820
+12% +$59.2K
IONS icon
57
Ionis Pharmaceuticals
IONS
$9.66B
$571K 0.4%
7,200
– –
AGMB
58
AgomAb Therapeutics NV
AGMB
$730M
$565K 0.39%
43,500
– –
BMRN icon
59
BioMarin Pharmaceuticals
BMRN
$12.9B
$541K 0.38%
9,450
– –
ONC
60
BeOne Medicines Ltd
ONC
$41B
$533K 0.37%
1,870
– –
HUM icon
61
Humana
HUM
$48.8B
$497K 0.35%
+1,250
New +$356K
JAZZ icon
62
Jazz Pharmaceuticals
JAZZ
$16.1B
$422K 0.29%
1,750
– –
RPRX icon
63
Royalty Pharma
RPRX
$28.4B
$404K 0.28%
7,200
– –
BIIB icon
64
Biogen
BIIB
$33.2B
$400K 0.28%
1,850
– –
MLYS icon
65
Mineralys Therapeutics
MLYS
$2.5B
$393K 0.27%
14,565
-17,053
-54% -$468K
ILMN icon
66
Illumina
ILMN
$33.5B
$375K 0.26%
2,132
– –
AXSM icon
67
Axsome Therapeutics
AXSM
$10.9B
$367K 0.26%
1,500
– –
SNDX icon
68
Syndax Pharmaceuticals
SNDX
$1.85B
$343K 0.24%
15,680
-16,000
-51% -$333K
RVMD icon
69
Revolution Medicines
RVMD
$45.2B
$343K 0.24%
1,830
– –
ABVX
70
Abivax
ABVX
$9.95B
$312K 0.22%
2,340
– –
BBIO icon
71
BridgeBio Pharma
BBIO
$14.7B
$305K 0.21%
4,100
-4,000
-49% -$280K
MRNA icon
72
Moderna
MRNA
$59.4B
$305K 0.21%
4,350
– –
GH icon
73
Guardant Health
GH
$21.6B
$297K 0.21%
1,980
– –
INCY icon
74
Incyte
INCY
$25.9B
$266K 0.19%
2,350
– –
ORIC icon
75
Oric Pharmaceuticals
ORIC
$1.32B
$255K 0.18%
23,500
– –
1 2
3
4

Similar funds

ICMP
Integrated Capital Management (Pennsylvania) Jessup, Pennsylvania $143M AUM 18.2% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
SL
Sonnipe Ltd Douglas, Isle Of Man $143M AUM 76.98% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Sectoral Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Sectoral Asset Management held 91 positions worth $143M, up 19% from $121M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Sectoral Asset Management deployed $11.4M of net new capital in Q2 2026, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was iRhythm Holdings: 26,070 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $905K trimmed.

  • Sectoral Asset Management's largest Q2 2026 buy was iRhythm Holdings: 26,070 shares worth $3.1M.
  • Sectoral Asset Management added most to Summit Therapeutics in Q2 2026, an estimated $2.67M increase.
  • Sectoral Asset Management's biggest Q2 2026 reduction was Gilead Sciences, cutting an estimated $905K.
  • Sectoral Asset Management fully exited Evommune Inc in Q2 2026, selling an estimated $13.5M.
  • Sectoral Asset Management's ten largest holdings make up 40% of its $143M portfolio in Q2 2026.
  • Sectoral Asset Management opened 14 new positions and closed 9 in Q2 2026.
  • Sectoral Asset Management's portfolio value rose 19% quarter-over-quarter to $143M.

Based on Sectoral Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.